Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology

Part IIIa: Therapy response monitoring in breast cancer, lymphoma and gliomas


Positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) is considered to be a very useful adjunct to anatomic imaging techniques and is now primarily used for oncological indications. These indications include diagnosis, staging, and therapy monitoring. In this review, we discuss the articles in which FDG-PET is clinically used for monitoring therapy in breast cancer, lymphomas and gliomas. It is found that the amount of FDG uptake strongly correlates with response to therapy in breast cancer, lymphomas, and gliomas; a decrease in FDG uptake after therapy indicates a positive response to therapy. However, this conclusion is based on small patient numbers, whereas the exact response mechanism is still unknown. Therefore, more studies in comparable patient groups are required to achieve a better understanding of FDG uptake patterns after therapy. Part IIIb deals with lung, and head and neck cancer, hepatocellular and colorectal tumours, and sarcoma.

This is a preview of subscription content, log in to check access.

Author information

Additional information

Received: 2 May 2000 / Accepted: 28 July 2000

Rights and permissions

Reprints and Permissions

About this article

Cite this article

van der Hiel, B., Pauwels, E. & Stokkel, M. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology . J Cancer Res Clin Oncol 127, 269–277 (2001).

Download citation

  • Key words FDG-PET
  • Therapy monitoring
  • Breast cancer
  • Lymphoma
  • Gliomas